Citius Pharma to spinoff its immunotherapy I/ONTAK into a new publicly-traded company

May 25, 2022 9:05 AM ETCitius Pharmaceuticals, Inc. (CTXR)By: Anuron Mitra, SA News Editor2 Comments

Business concept.Top view of glasses,clock,pen and tablet written with Spinoff on white wooden background.

Mohamad Faizal Bin Ramli/iStock via Getty Images

  • Late-stage biopharmaceutical company Citius Pharmaceuticals (NASDAQ:CTXR) on Wednesday said it plans to split into two separate publicly-traded entities.
  • CTXR said it would form a new company focused on developing and commercializing its

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.